Spotlight Innovation Inc. Updates Its Company Overview for Prospective Buyers of Its Shares, Investors and Current Shareholders
February 04 2016 - 08:38AM
InvestorsHub NewsWire
SOURCE: Spotlight Innovation Inc.
|
WEST DES MOINES, IA--(NewMediaWire - Feb 4, 2016) -
Spotlight Innovation Inc. (OTCQB: STLT)
on February 3, 2016, filed a Form 8-K containing a Company Overview
presentation it plans to present to prospective buyers of its
shares, investors and current shareholders. The Company Overview
presentation can be found on the Company's website at www.spotlightinnovation.com/investors.
Cris Grunewald, President and Chief Executive Officer of
Spotlight Innovation, said, "We have made continued and meaningful
advances over the past few months and believe that now is an
appropriate time to increase our visibility with the investment
community. We are most pleased with the progress we have made with
our cancer and infectious disease platform biotechnologies, and we
encourage investors and shareholders to review our updated investor
presentation."
About Spotlight Innovation Inc.
Spotlight Innovation Inc. (OTCQB: STLT)
identifies and acquires rights to innovative and proprietary
platform technology candidates with a focus on cancer drugs and
related treatment therapies, solutions for infectious disease, and
other specialty and unique opportunities. Access to platform
technology candidates is accomplished via our extensive
relationships with many leading academic institutions and other
sources. We provide value-added development capability and funding
in order to accelerate development progress. When commercially
significant benchmarks have been achieved, we will partner with
proven market leaders via sale, out-license or strategic alliance.
For more information, visit www.spotlightinnovation.com or follow us
on www.twitter.com/spotlightinno.
Forward Looking Statements
Statements in this press release that are not purely historical
are forward-looking statements. Forward-looking statements herein
include statements regarding the Company's efforts to develop and
commercialize its various technologies. Actual outcomes and the
Company's actual results could differ materially from those in such
forward-looking statements. Factors that could cause actual results
to differ materially include risks and uncertainties such as the
inability to finance the planned development of the technologies,
the inability to hire appropriate staff to develop the
technologies, unforeseen technical difficulties in developing the
technologies, the inability to obtain regulatory approval for human
use, competitors' therapies proving to be more effective, cheaper
or otherwise more preferable, the inability to market a product,
all of which could, among other things, delay or prevent product
release, as well as other factors expressed from time to time in
Spotlight Innovation's periodic filings with the Securities and
Exchange Commission (the "SEC"). As a result, this press release
should be read in conjunction with Spotlight Innovation's periodic
filings with the SEC. The forward-looking statements contained
herein are made only as of the date of this press release and
Spotlight Innovation undertakes no obligation to publicly update
such forward-looking statements to reflect subsequent events or
circumstances.